# CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab

> **NCT05121038** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Anup Kasi** · enrollment: 50 (estimated)

## Conditions studied

- Colon Cancer
- Pancreas Cancer
- Digestive Cancer

## Interventions

- **DRUG:** CEND-1
- **DRUG:** Panitumumab
- **DRUG:** Folfirinox

## Key facts

- **NCT ID:** NCT05121038
- **Lead sponsor:** Anup Kasi
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-20
- **Primary completion:** 2025-09
- **Final completion:** 2026-09
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05121038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05121038, "CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05121038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*